Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/433—Thidiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

• Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), controls multiple cellular regulatory processes by removing phosphate groups from tyrosine substrates.
• PTPN2 is ubiquitously expressed, but expression is highest in hematopoietic and placental cells (Mosinger, B. Jr. et al., Proc Natl Acad Sci USA 89:499-503; 1992).
• PTPN2 expression is controlled post-transcriptionally by the existence of two splice variants: a 45 kDa form that contains a nuclear localization signal at the C-terminus upstream of the splice junction, and a 48 kDa canonical form which has a C-terminal ER retention motif (Tillmann U. et al., Mol Cell Biol 14:3030-3040; 1994).
• the 45 kDa isoform can passively transfuse into the cytosol under certain cellular stress conditions.
• PTPN2 negatively regulates signaling of non-receptor tyrosine kinases (e.g. JAK1, JAK3), receptor tyrosine kinases (e.g.
• PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNy.
• Protein tyrosine phosphatase non-receptor type 1 (PTPN1), also known as protein tyrosine phosphatase- IB (PTP1B), has been shown to play a key role in insulin and leptin signaling and is a primary mechanism for down-regulating both the insulin and leptin receptor signaling pathways (Kenner K. A. et al., J Biol Chem 271: 19810-19816, 1996). Animals deficient in PTPN1 have improved glucose regulation and lipid profiles and are resistant to weight gain when treated with a high fat diet (Elchebly M. et al., Science 283: 1544-1548, 1999). Thus, there is a medical need for PTPN1 inhibitors..
• the present disclosure is directed, at least in part, to compounds, for the inhibition of protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 ((PTPN1), also known as protein tyrosine phosphatase- IB (PTP1B)).
• protein tyrosine phosphatase e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 ((PTPN1), also known as protein tyrosine phosphatase- IB (PTP1B)
• protein tyrosine phosphatase e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatas
• R 1 is selected from the group consisting of -NH2, -N(R a )-C 1-8 alkyl, -N(R a )-C 2-6 alkenyl -N(R a )- C 1-6 alkylene-C 3 -6Cycloalkyl, — N(R a )-C(O)-O-C 1-6 alkyl, -N(R a )-C 1-6 alkylene-4-7 membered heterocyclyl, -N(R a )-C 1-6 alkylene-5-6 membered heteroaryl and -N(R a )-C 1-6 alkylene-phenyl; wherein -N(R a )-C 1-8 alkyl, -N(R a )-C 2-6 alkenyl -N(R a )-C 1-6 alkylene-C 3 -6Cycloalkyl, -N(R a )-
• C(O)-O-C 1-6 alkyl, -N(R a )-C 1-6 alkylene-4-7 membered heterocyclyl, -N(R a )-C 1-6 alkylene- 5-6 membered heteroaryl and -N(R a )-C 1-6 alkylene-phenyl may optionally be substituted on one or more available carbons by one, two, three or more substituents each independently selected from R g ; wherein if -N(R a )-C 1-6 alkylene-4-6 membered heterocyclyl or -N(R a )-C 1-6 alkylene-5-6 membered heteroaryl contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by R h ; and
• R g is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, C 1-6 alkyl, phenyl, and C 1-6 alkoxy, wherein C 1-6 alkyl, phenyl, or C 1-6 alkoxy may optionally be substituted by one, two three or more substituents each independently selected from R p ;
• R h is independently selected, for each occurrence, from the group consisting of C 1-6 alkyl and C 1- 6 alkyl-O-C(O)-;
• R p is independently selected, for each occurrence, from the group consisting of C 1-6 alkyl, halogen and hydroxyl;
• R a is independently selected, for each occurrence, from the group consisting of hydrogen and C 1- 6 alkyl.
• R 1 is selected from the group consisting of -NH2, -N(R a )-C 1-8 alkyl, -N(R a )-C 2-6 alkenyl -N(R a )- C 1-6 alkylene-C 3 -6Cycloalkyl, -N(R a )-C(O)-O-C 1-6 alkyl, -N(R a )-C 1-6 alkylene-4-7 membered heterocyclyl, -N(R a )-C 1-6 alkylene-5-6 membered heteroaryl and -N(R a )-C 1-6 alkylene-phenyl; wherein -N(R a )-C 1-8 alkyl, -N(R a )-C 2-6 alkenyl -N(R a )-C 1-6 alkylene-C 3 -6Cycloalkyl, -N(R a )-
• C(O)-O-C 1-6 alkyl, -N(R a )-C 1-6 alkylene-4-7 membered heterocyclyl, -N(R a )-C 1-6 alkylene- 5-6 membered heteroaryl and -N(R a )-C 1-6 alkylene-phenyl may optionally be substituted on one or more available carbons by one, two, three or more substituents each independently selected from R g ; wherein if -N(R a )-C 1-6 alkylene-4-6 membered heterocyclyl or -N(R a )-C 1-6 alkylene-5-6 membered heteroaryl contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by R h ; and
• R g is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, C 1-6 alkyl, phenyl, and C 1-6 alkoxy, wherein C 1-6 alkyl, phenyl, or C 1-6 alkoxy may optionally be substituted by one, two three or more substituents each independently selected from R p ;
• R h is independently selected, for each occurrence, from the group consisting of C 1-6 alkyl and C 1 - ealkyl-O-C(O)-;
• R p is independently selected, for each occurrence, from the group consisting of C 1-6 alkyl, halogen and hydroxyl;
• R a is independently selected, for each occurrence, from the group consisting of hydrogen and C 1- 6 alkyl.
• R 1 is selected from the group consisting of -NH2, -N(R a )-C 1- 8 alkyl, -N(R a )-C 2-6 alkenyl -N(R a )-C 1-6 alkylene-C 3 -6Cycloalkyl, — N(R a )-C(O)-O-C 1-6 alkyl, - N(R a )-C 1-6 alkylene-4-7 membered heterocyclyl, -N(R a )-C 1-6 alkylene-5-6 membered heteroaryl and -N(R a )-C 1-6 alkylene-phenyl; wherein -N(R a )-C 1-8 alkyl, -N(R a )-C 2-6 alkenyl -N(R a )-C 1-6 alkylene-C 3 -6Cycloalkyl, -N(R a )-
• R 1 is -N(H)-C 1-8 alkyl, wherein C 1-8 alkyl is optionally substituted with R g . In some embodiments, R 1 is -N(H)-C 1-8 alkyl. In some embodiments, R 1 is -N(H)-C 1- 6 alkyl, wherein C 1-6 alkyl is optionally substituted with R g .
• R 1 is -N(H)- C 1-8 alkyl, wherein C 1-8 alkyl is optionally substituted with R g , wherein R g is selected from fluoro, hydroxyl, C 1-6 alkyl, and C 1-6 alkoxy, wherein C 1-6 alkyl, and C 1-6 alkoxy are optionally substituted by one, two three or more substituents selected from R p ; and R p is independently selected, for each occurrence, from halogen.
• R 1 is -N(H)-C 1-8 alkyl, wherein C 1-8 alkyl is substituted with one or two instances of halogen, C 1-6 alkyl, or C 1-6 alkoxy.
• R 1 is selected from the group consisting of
• R 1 is -N(H)-C 1-6 alkylene-C 3 -6Cycloalkyl, wherein R 1 may optionally be substituted by one, two, three or more substituents each independently selected from R g .
• R 1 is -N(H)-C 1-6 alkylene-C 3 -6Cycloalkyl may optionally be substituted by one, two, three or more substituents, R g ; wherein R g is independently selected, for each occurrence, from the group consisting of fluoro, C 1-6 alkyl, and phenyl, wherein C 1-6 alkyl and phenyl are optionally substituted by one, two three or more substituents selected from R p ; and R p is independently selected, for each occurrence, from fluoro or hydroxyl.
• R 1 is selected from the group consisting of
• R 1 is -N(H)-C 1-6 alkylene-4-6 membered heterocyclyl, wherein R 1 may optionally be substituted by one, two, three or more substituents each independently selected from R g , wherein if 4-7 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by R h .
• R 1 is - N(H)-C 1-6 alkylene-4-6 membered heterocyclyl, wherein R 1 is substituted with one, two, three or more substituents each independently selected from R g , wherein if 4-7 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by R h .
• R 1 is -N(H)-C 1-6 alkylene-4-6 membered heterocyclyl, wherein R 1 is substituted with one, two, three or more substituents each independently selected from R g , wherein if 4-7 membered heterocyclyl contains a substitutable ring nitrogen atom, that ring nitrogen atom may optionally be substituted by R h , and R h is C 1-6 alkyl-O-C(O)-.
• R 1 is -N(H)-C 1-6 alkylene-4-6 membered heterocyclyl, wherein R 1 may optionally be substituted by one, two, three or more substituents each independently selected from the group consisting of fluorine, C 1-6 alkyl, and phenyl, wherein C 1-6 alkyl may optionally be substituted by one, two or three fluorine.
• R 1 is selected from the group consisting of
• R 1 is -N(H)-C 1-6 alkylene-phenyl, wherein R 1 may optionally be substituted on one or more available carbons by one, two, three or more substituents each independently selected from R g .
• R 1 is -N(H)-C 1-6 alkylene-phenyl, wherein R 1 may optionally be substituted on one or more available carbons by one, two, three or more substituents each independently selected from R g , and R g is independently, for each occurrence, C 1-6 alkyl.
• R 1 is selected from the group consisting of
• R 1 is -N(H)-C 1-6 alkylene-5-6 membered heteroaryl, wherein R 1 may optionally be substituted on one or more available carbons by one, two, three or more substituents each independently selected from R g .
• R 1 is -N(H)-C 1 - 6 alkylene-5-6 membered heteroaryl, wherein R 1 may optionally be substituted on one or more available carbons by one, two, three or more substituents each independently selected from R g , and R g is independently, for each occurrence, C 1-6 alkyl.
• R 1 is
• the present disclosure includes a compound selected from the group consisting of
• a compound disclosed herein is formulated as a pharmaceutically acceptable composition comprising a disclosed compound and a pharmaceutically acceptable carrier.
• disclosed herein is a method of treating non-small cell lung cancer in a patient in need thereof comprising administering to the patient an effective amount of a compound disclosed herein.
• the compounds of the present disclosure may be better understood in connection with the following synthetic schemes and methods which illustrate a means by which the compounds can be prepared.
• the compounds of the present disclosure can be prepared by a variety of synthetic procedures. Representative synthetic procedures are shown in, but not limited to, Scheme 1.
• Scheme 1 Representative scheme for synthesis of exemplary compounds of the disclosure.
• Compounds of formula (1-2) can be reductively aminated with aldehydes, R 1 - 1 -C HO.
• R 1 - 1 is optionally substituted C 1-6 alkyl, optionally substituted C 1-6 alkenyl, optionally substituted 3-7-membered heteroalkyl, optionally substituted -C 1-5 alkylene-C 3-6 cycloalkyl, optionally substituted -C 1-5 alkylene-C 3-6 cycloalkenyl, optionally substituted -C 1-5 alkylene-C 6 - 10 aryl, optionally substituted -C 1-5 alkylene-4-6 membered heteroaryl or optionally substituted - C 1-5 alkylene-4-6 membered heterocyclyl, to give compounds of formula (1-2).
• compositions comprising a compound disclosed herein, e.g., a compound of Formula (I).
• the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.
• a compound disclosed herein, e.g., a compound of Formula (I) is provided in an effective amount in the pharmaceutical composition.
• the effective amount is a therapeutically effective amount.
• the effective amount is a prophylactically effective amount.
• compositions provided by the present disclosure include compositions wherein the active ingredient (e.g., compounds described herein, including embodiments or examples) is contained in a therapeutically effective amount, i. e. , in an amount effective to achieve its intended purpose.
• a therapeutically effective amount i. e. , in an amount effective to achieve its intended purpose.
• the actual amount effective for a particular application will depend, inter aha, on the condition being treated.
• such compositions When administered in methods to treat a disease, such compositions will contain an amount of active ingredient effective to achieve the desired result, e.g. , inhibiting the activity of a target molecule (e.g. PTPN2 and/or PTPN 1), and/or reducing, eliminating, or slowing the progression of disease symptoms.
• a target molecule e.g. PTPN2 and/or PTPN 1
• Determination of a therapeutically effective amount of a compound disclosed herein is well within the capabilities of those skilled in the art, especially in light of the detailed
• analogue means one analogue or more than one analogue.
• C 1 -C 6 alkyl is intended to encompass, C 1 , C2, C 3 , C4, C 5 , C 6 , C1-C 6 , C1-C 5 , C1-C4, C1-C 3 , C1-C2, C2-C 6 , C2-C 5 , C2-C4, C2-C 3 , C 3 -C 6 , C 3 -C 5 , C 3 -C4, C4-C 6 , C 4 - C 5 , and C 5 -C 6 alkyl.
• Alkyl refers to a radical of a straight-chain or branched saturated hydrocarbon group having from 1 to 20 carbon atoms (“C1-C20 alkyl”). In some embodiments, an alkyl group has 1 to 12 carbon atoms (“C1-C12 alkyl”). In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1 -C 8 alkyl”). In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1 -C 6 alkyl”). In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C1-C 5 alkyl”). In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C1-C4 alkyl”).
• an alkyl group has 1 to 3 carbon atoms (“C1-C 3 alkyl”). In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C1-C2 alkyl”). In some embodiments, an alkyl group has 1 carbon atom (“C 1 alkyl”). In some embodiments, an alkyl group has 2 to 6 carbon atoms (“C2-C 6 alkyl”).
• C 1 -C 6 alkyl groups include methyl (C 1 ), ethyl (C2), n-propyl (C 3 ), isopropyl (C 3 ), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C 5 ), 3-pentanyl (C 5 ), amyl (C 5 ), neopentyl (C 5 ), 3-methyl-2-butanyl (C 5 ), tertiary amyl (C 5 ), and n-hexyl (C 6 ).
• alkyl groups include n-heptyl (C 7 ), n-octyl (C 8 ) and the like.
• Each instance of an alkyl group may be independently optionally substituted, i. e. , unsubstituted (an “unsubstituted alkyl”) or substituted (a “substituted alkyl”) with one or more substituents; e.g., for instance from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
• the alkyl group is unsubstituted C1-10 alkyl (e.g., -CH 3 ).
• the alkyl group is substituted C1-6 alkyl.
• alkylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, - CH 2 CH 2 CH 2 CH 2 -. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present disclosure.
• alkenylene by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene.
• An alkylene group may be described as, e.g., a C 1 -C 6 - membered alkylene, wherein the term “membered” refers to the non-hydrogen atoms within the moiety.
• Alkenyl refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 20 carbon atoms, one or more carbon-carbon double bonds, and no triple bonds (“C2- C20 alkenyl”).
• an alkenyl group has 2 to 10 carbon atoms (“C2-C10 alkenyl”).
• an alkenyl group has 2 to 8 carbon atoms (“C 2 -C 8 alkenyl”).
• an alkenyl group has 2 to 6 carbon atoms (“C2-C 6 alkenyl”).
• an alkenyl group has 2 to 5 carbon atoms (“C2-C 5 alkenyl”).
• an alkenyl group has 2 to 4 carbon atoms (“C2-C4 alkenyl”). In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C2-C 3 alkenyl”). In some embodiments, an alkenyl group has 2 carbon atoms (“C2 alkenyl”).
• the one or more carboncarbon double bonds can be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl).
• Examples of C2-C4 alkenyl groups include ethenyl (C2), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1- butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like.
• C2-C 6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ), and the like. Additional examples of alkenyl include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 ), and the like.
• Each instance of an alkenyl group may be independently optionally substituted, e.g., unsubstituted (an “unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) with one or more substituents, e.g., from 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.
• the alkenyl group is unsubstituted C2-10 alkenyl.
• the alkenyl group is substituted C2-6 alkenyl.
• Aryl refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 71 electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system (“C 6 -C14 aryl”).
• an aryl group has six ring carbon atoms (“C 6 aryl”; e.g., phenyl).
• an aryl group has ten ring carbon atoms (“C 10 aryl”; e.g., naphthyl such as 1- naphthyl and 2-naphthyl). In some embodiments, an aryl group has fourteen ring carbon atoms (“C 14 aryl”; e.g., anthracyl).
• An aryl group may be described as, e.g., a C 6 -C 1 o-membered aryl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.
• Aryl groups include, but are not limited to, phenyl, naphthyl, indenyl, and tetrahydronaphthyl. Each instance of an aryl group may be independently optionally substituted, e.g., unsubstituted (an “unsubstituted aryl”) or substituted (a “substituted aryl”) with one or more substituents. In certain embodiments, the aryl group is unsubstituted C 6 -C14 aryl. In certain embodiments, the aryl group is substituted C 6 -C 14 aryl.
• alkoxy refers to an — O-alkyl radical, wherein the alkyl residues is as defined above, and which is attached via an oxygen atom.
• Halo or “halogen,” independently or as part of another substituent, mean, unless otherwise stated, a fluorine (F), chlorine (Cl), bromine (Br), or iodine (I) atom.
• halide by itself or as part of another substituent, refers to a fluoride, chloride, bromide, or iodide atom. In certain embodiments, the halo group is either fluorine or chlorine.
• haloalkyl are meant to include monohaloalkyl and polyhaloalkyl.
• halo-C 1 -C 6 alkyl includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3- bromopropyl, and the like.
• Heteroaryl refers to a radical of a 5-10 membered monocyclic 4n+2 aromatic ring system (e.g., having 6 or 10 ⁇ electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur (“5-10 membered heteroaryl”).
• heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits.
• a heteroaryl group may be described as, e.g.
• a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”).
• a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”).
• a heteroaryl group is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”).
• the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
• Each instance of a heteroaryl group may be independently optionally substituted, i.e., unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.
• the heteroaryl group is unsubstituted 5-14 membered heteroaryl.
• the heteroaryl group is substituted 5-14 membered heteroaryl.
• Exemplary 5-membered heteroaryl groups containing one heteroatom include, without limitation, pyrrolyl, furanyl and thiophenyl.
• Exemplary 5-membered heteroaryl groups containing two heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl.
• Exemplary 5-membered heteroaryl groups containing three heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl.
• Exemplary 6-membered heteroaryl groups containing one heteroatom include, without limitation, pyridinyl.
• Exemplary 6-membered heteroaryl groups containing two heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl.
• Cycloalkyl refers to a radical of a non-aromatic cyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C 3 -C10 cycloalkyl”) and zero heteroatoms in the non-aromatic ring system.
• a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3 - C 8 cycloalkyl”).
• a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3 -C 6 cycloalkyl”).
• a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3 -C 6 cycloalkyl”).
• a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5 -C10 cycloalkyl”).
• a cycloalkyl group may be described as, e.g., a C4-C?-membered cycloalkyl, wherein the term “membered” refers to the non-hydrogen ring atoms within the moiety.
• Exemplary C 3 -C 6 cycloalkyl groups include, without limitation, cyclopropyl (C 3 ), cyclopropenyl ( C 3 ), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ), and the like.
• Exemplary C 3 -C 8 cycloalkyl groups include, without limitation, the aforementioned C 3 -C 6 cycloalkyl groups as well as cycloheptyl (C 7 ), cycloheptenyl (C 7 ), bicyclof l. l.l]pentanyl (C 5 ), bicyclo[2.2.2]octanyl (C 8 ), bicyclo[2.1.1]hexanyl (C 6 ), bicyclo [3. l.l]heptanyl (C 7 ), bicyclo [3.1.0]hexanyl and the like.
• the cycloalkyl group is either monocyclic (“monocyclic cycloalkyl”) or contain a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic cycloalkyl”) and can be saturated or can be partially unsaturated.
• a cycloalkyl group may be independently optionally substituted, e.g., unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents.
• the cycloalkyl group is unsubstituted C 3 -C10 cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C 3 -C10 cycloalkyl.
• “cycloalkyl” is a monocyclic, saturated cycloalkyl group having from 3 to 10 ring carbon atoms (“C 3 -C10 cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms (“C 3 -C 8 cycloalkyl”).
• a cycloalkyl group has 3 to 6 ring carbon atoms (“C 3 -C 6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C 5 -C 6 cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms (“C 5 -C10 cycloalkyl”). Examples of C 5 -C 6 cycloalkyl groups include cyclopentyl (C 5 ) and cyclohexyl (C 5 ).
• C 3 -C 6 cycloalkyl groups include the aforementioned C 5 -C 6 cycloalkyl groups as well as cyclopropyl (C 3 ) and cyclobutyl (C4).
• C 3 -C 8 cycloalkyl groups include the aforementioned C 3 -C 6 cycloalkyl groups as well as cycloheptyl (C 7 ) and cyclooctyl (C 8 ).
• each instance of a cycloalkyl group is independently unsubstituted (an “unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”) with one or more substituents.
• the cycloalkyl group is unsubstituted C 3 -C10 cycloalkyl.
• the cycloalkyl group is substituted C 3 -C10 cycloalkyl.
• Heterocyclyl refers to a radical of a 3- to 10-membered nonaromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“3-10 membered heterocyclyl”).
• the point of attachment can be a carbon or nitrogen atom, as valency permits.
• a heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”), and can be saturated or can be partially unsaturated.
• Heterocyclyl bicyclic ring systems can include one or more heteroatoms in one or both rings.
• Heterocyclyl also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more cycloalkyl groups wherein the point of attachment is either on the cycloalkyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system.
• a heterocyclyl group may be described as, e.g., a 3-7-membered heterocyclyl, wherein the term “membered” refers to the non-hydrogen ring atoms, i.e., carbon, nitrogen, oxygen, sulfur, boron, phosphorus, and silicon, within the moiety.
• Each instance of heterocyclyl may be independently optionally substituted, e.g., unsubstituted (an “unsubstituted heterocyclyl”) or substituted (a “substituted heterocyclyl”) with one or more substituents.
• the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl.
• the heterocyclyl group is substituted 3-10 membered heterocyclyl.
• a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”).
• a heterocyclyl group is a 5-8 membered non- aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”).
• a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”).
• the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
• the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
• Exemplary 4-membered heterocyclyl groups containing one heteroatom include, without limitation, azetidinyl, oxetanyl and thietanyl.
• Exemplary 5-membered heterocyclyl groups containing one heteroatom include, without limitation, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl and pyrrolyl-2, 5-dione.
• Exemplary 5-membered heterocyclyl groups containing two heteroatoms include, without limitation, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one.
• Exemplary 5- membered heterocyclyl groups containing three heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl.
• Exemplary 6-membered heterocyclyl groups containing one heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl.
• Exemplary 6-membered heterocyclyl groups containing two heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl.
• Exemplary 5-membered heterocyclyl groups fused to a C 6 aryl ring include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, and the like.
• Exemplary 6- membered heterocyclyl groups fused to an aryl ring include, without limitation, tetrahydroquinolinyl, tetrahydroisoquinolinyl, 3,4- dihydro-2H- 1 -benzothiopyran, and the like.
• Haldroxy or “hydroxyl” refers to the radical -OH.
• one or more of the nitrogen atoms of a disclosed compound if present are oxidized to the corresponding /V-oxide.
• Alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups, as defined herein, are optionally substituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or “unsubstituted” cycloalkyl, “substituted” or “unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or “substituted” or “unsubstituted” heteroaryl group).
• substituted means that at least one hydrogen present on a group (e.g. , a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
• a “substituted” group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position.
• substituted is contemplated to include substitution with all permissible substituents of organic compounds, such as any of the substituents described herein that result in the formation of a stable compound.
• the present disclosure contemplates any and all such combinations in order to arrive at a stable compound.
• heteroatoms such as nitrogen may have hydrogen substituents and/or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and results in the formation of a stable moiety.
• Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups.
• Such so-called ring -forming substituents are typically, though not necessarily, found attached to a cyclic base structure.
• the ring -forming substituents are attached to adjacent members of the base structure.
• two ringforming substituents attached to adjacent members of a cyclic base structure create a fused ring structure.
• the ring-forming substituents are attached to a single member of the base structure.
• two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure.
• the ringforming substituents are attached to non-adjacent members of the base structure.
• Treating” or “treatment” refers to a method of alleviating or abrogating a disease and/or its attendant symptoms.
• the compounds disclosed herein are useful in the treatment of non-small cell lung cancer.
• a method of treating a human subject with non-small cell lung cancer comprising administering to the human subject in need thereof a therapeutically effective amount of a compound of formula (I) is provided.
• terapéuticaally effective amount refers to an amount of a compound, or a pharmaceutically acceptable salt thereof, sufficient to prevent the development of or to alleviate to some extent one or more of the symptoms of the condition or disorder being treated when administered for treatment in a particular subject or subject population.
• subject refers to a human.
• human patient
• subject are used interchangeably herein.
• the term “inhibition”, “inhibit”, “inhibiting” and the like in reference to a protein-inhibitor (e.g., antagonist) interaction means negatively affecting (e.g., decreasing) the activity or function of the protein relative to the activity or function of the protein in the absence of the inhibitor.
• Patient or “subject” in need thereof refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a compound or pharmaceutical composition, as provided herein.
• a patient is human.
• “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient.
• PTPN2 refers to protein tyrosine phosphatase non-receptor type 2.
• PTPN1 refers to protein tyrosine phosphatase non-receptor type 1 (PTPN1), also known as protein tyrosine phosphatase- IB (PTP1B),
• a compound disclosed herein is formulated as a pharmaceutically acceptable composition comprising a disclosed compound and a pharmaceutically acceptable carrier.
• protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
• suitable protecting group for a particular functional group as well as suitable conditions for protection and deprotection are well known in the art. For example, numerous protecting groups, and their introduction and removal, are described in Greene et al. , Protecting Groups in Organic Synthesis, Second Edition, Wiley, New York, 1991, and references cited therein.
• APCI atmospheric pressure chemical ionization
• DMSO dimethyl sulfoxide
• ESI electrospray ionization
• HPLC high performance liquid chromatography
• MS mass spectrum
• NMR nuclear magnetic resonance
• ppm parts per million
• v/v volume/volume.
• Triethylamine (0.06 mL, 0.45 mmol, 3.0 equivalents) and a solution of 4,4- difluorobutanal in dichloromethane (-25% weight, 193 mg, 0.45 mmol, 3.0 equivalents) were added in sequence to a suspension of the product of Example 3P (nominally 0.15 mmol, 1 equivalent) in 50% ethanol-dichloromethane (0.80 mL, -0.2 M) at 23 °C.
• the reaction mixture was stirred for 2 hours at 23 °C.
• Sodium borohydride (22.5 mg, 0.60 mmol, 4.0 equivalents) was added at 23 °C.
• the reaction mixture was stirred for 20 minutes at 23 °C.
• the mixture was diluted with aqueous hydrochloric acid (3 M, 0.20 mL; CAUTION: gas evolution!), water (1.0 mL) and dimethyl sulfoxide (1.0 mL).
• the diluted mixture was partially concentrated.
• the partially concentrated mixture was purified by preparative high-performance liquid chromatography (Phenomenex® C8(2) Luna® 5 pm, AXIATM 30 x 75 mm [3 columns coupled], elution with a gradient of 5-100% 0.1% trifluoroacetic acid-acetonitrile -water [v/v]) to furnish the title compound (19 mg, 24% over 3 steps).
• Example 2A methyl ( ⁇ (3S)-7-(benzyloxy)-3-[(tert-butoxycarbonyl)amino]-5-fluoro-3,4-dihydro- 2H-1 -benzothiopyran-6-yl ⁇ amino)acetate
• Example 2B methyl [ ⁇ (3S)-7-(benzyloxy)-3-[(tert-butoxycarbonyl)amino]-5-fluoro-3,4-dihydro- 2H-l-benzothiopyran-6-yl ⁇ ( ⁇ [(prop-2-en-l-yl)oxy]carbonyl ⁇ sulfamoyl)amino]acetate
• Example 2C tert-butyl [(3S)-7-(benzyloxy)-5-fluoro-6-(1,1,4-trioxo-l ⁇ 6 ,2,5-thiadiazolidin-2-yl)-
• Example 2D tert-butyl [(3S)-5-fluoro- 7-hydroxy-6-(l, 1, 4-trioxo-1 ⁇ 6 , 2, 5-thiadiazolidin-2-yl)- 3, 4-dihydro-2H-1 -benzothiopyran- 3-yl ] carbamate
• a solution of potassium tert-butoxide in tetrahydrofuran (1.0 M, 44.0 mL, 44.0 mmol, 1.1 equivalents) was added slowly down the side of the reaction vessel to a suspension of benzyl alcohol (4.60 mL, 44.2 mmol, 1.1 equivalents) and 5 -bromo- 1, 3 -difluoro-2 -nitrobenzene (10.0 g, 42.0 mmol, 1 equivalent) in tetrahydrofuran (200 mL, 0.21 M) at -67 °C at a rate such that the internal temperature did not exceed -57 °C. The reaction mixture was stirred for 5 minutes such that the internal temperature did not exceed -57 °C.
• the product mixture was then diluted sequentially with saturated aqueous ammonium chloride solution (10 mL), water (50 mL), and ethyl acetate (100 mL) at -78 °C.
• the diluted product mixture was warmed over 30 minutes to 23 °C.
• the resulting biphasic mixture was then transferred to a separatory funnel and the layers that formed were separated.
• the aqueous layer was extracted with ethyl acetate (50 mL).
• the organic layers were combined and the combined organic layers were washed with saturated aqueous sodium chloride solution (50 mL).
• the washed organic layer was dried over sodium sulfate.
• the dried solution was fdtered and the filtrate was concentrated.
• Trifluoroacetic anhydride (5.90 mL, 41.8 mmol, 1.2 equivalents) was added over 10 minutes via syringe pump to a solution of the product of Example 3B (nominally 34.7 mmol, 1 equivalent) in dichloromethane (174 mL, 0.2 M) at 0 °C such that the internal temperature did not exceed 7 °C.
• the reaction mixture was warmed over 18 hours to 23 °C.
• the product mixture was partitioned between water (50 mL) and ethyl acetate (500 mL). The organic layer was washed sequentially with hydrochloric acid solution (1 M, 3 x 100 mL) and saturated aqueous sodium chloride solution (100 mL).
• Example 3D tert-butyl [(2S)-l-[4-(benzyloxy)-6-bromo-2-fluoro-3-(2,2,2- trifluoroacetamido)phenyl ]-3- ⁇ [tert-butyl(dimethyl)silyl ]oxy ⁇ propan-2-yl ] carbamate
• the resulting mixture was warmed over 20 minutes to 23 °C.
• the warmed mixture was diluted with ethyl acetate (100 mL).
• the resulting biphasic mixture was transferred to a separatory funnel and the layers that formed were separated.
• the aqueous layer was extracted with ethyl acetate (50 mL).
• the organic layers were combined and the combined organic layers were washed with saturated aqueous sodium chloride solution (20 mL).
• the washed organic layer was dried over sodium sulfate.
• the dried solution was filtered and the filtrate was concentrated.
• the residue obtained was dissolved in ether (20 mL).
• Diatomaceous earth ⁇ 10 g was added to the solution and the mixture was concentrated.
• Example 3E methyl [ ⁇ 6-(benzyloxy)-4-bromo-3-[(2S)-2-[(tert-butoxycarbonyl)amino]-3- ⁇ [tert- butyl(dimethyl) silyl ]oxy ⁇ propyl ]-2-fluorophenyl ⁇ (trifluoroacetyl)amino ] acetate
• Example 3F methyl ⁇ [6-(benzyloxy)-4-bromo-3- ⁇ (2S)-2-[(tert-butoxycarborryl)amino]-3- hydroxypropyl ⁇ -2-fluorophenyl ]( trifluoroacetyl)amino ⁇ acetate
• Example 3G methyl ⁇ [6-(benzyloxy)-4-bromo-3- ⁇ (2S)-2-[(tert-butoxycarbonyl)amino]-3- [(methanesulfonyl)oxy]propyl ⁇ -2-fluorophenyl ]( trifluoroacetyl)amino ⁇ acetate
• Example 31 methyl [ ⁇ (3S)-7-(henzyloxy)-3-[(tert-hutoxycarhonyl)amino]-5-fluoro-3,4-dihydro- 2H-l-henzothiopyran-6-yl ⁇ (trifluoroacetyl)amino]acetate
• the reaction vessel was placed in a heating block that had been preheated to 100 °C.
• the reaction mixture was stirred for 45 minutes at 100 °C.
• the product mixture was cooled to 23 °C.
• the reaction mixture was diluted with ethyl acetate (5 mL). Diatomaceous earth (-1 g) was added to the solution, and the mixture was concentrated.
• the residue obtained was purified by flash column chromatography (40 g Teledyne ISCO RediSep Rf Gold® silica column, elution with a gradient from 0—100% ethyl acetate— heptanes) to furnish the title compound (1.49 g, 51%).
• MS (APCI + ) m/z 573 [M+H] + .
• Example 3 J methyl ⁇ [(3S)-3-amino-5-fluoro-7-hydroxy-3,4-dihydro-2H-l-henzothiopyran-6- yl ]( trifluoroacetyl)amino ⁇ acetate
• Example 3K methyl [ ⁇ (3S)-3-[(tert-hutoxycarhonyl)amino]-5-fluoro-7-hydroxy-3,4-dihydro- 2H-l-henzothiopyran-6-yl ⁇ (trifluoroacetyl)amino]acetate
• Example 3L methyl [ ⁇ (3S)-3-[(tert-butoxycarbonyl)amino]-5-fluoro-7-[(2- methoxyethoxy)methoxy]-3, 4-dihydro-2H-l -benzothiopyran-6-yl ⁇ ( trifluoroacetyl)amino ] acetate
• 2-Methoxyethoxymethyl chloride (1.07 mL, 9.48 mmol, 1.2 equivalents) was added to a solution of the product of Example 3K (3.81 g, 7.90 mmol, 1 equivalent) and A.A- diisopropylethylamine (4.14 mL, 23.7 mmol, 3.0 equivalents) in dichloromethane (40.0 mL, 0.2 M) at 0 °C.
• the reaction vessel was immediately removed from its cooling bath and warmed to 23 °C over 1 hour. Additional 2-methoxyethoxymethyl chloride (0.20 mL, 1.77 mmol, 0.22 equivalent) was added at 23 °C. The reaction mixture was stirred for 30 minutes at 23 °C. The product mixture was partitioned between ethyl acetate (250 mL), heptanes (20 mL), water (10 mL), and saturated aqueous ammonium chloride solution (30 mL). The organic layer was separated and then washed with saturated aqueous sodium chloride solution (30 mL). The washed organic layer was dried over sodium sulfate. The dried solution was fdtered and the fdtrate was concentrated. The title compound obtained was used without further purification in the following step. MS (APCI + ) m/z 471 [M+H-C(O)OC(CH 3 )3] + .
• Example 3M methyl ( ⁇ (3S)-3-[(tert-butoxycarbonyl)amino]-5-fluoro-7-[(2- methoxyethoxy)methoxy]-3, 4-dihydro-2H-l-benzothiopyran-6-yl ⁇ amino)acetate
• a solution of sodium methoxide in methanol 0.5 M, 8.00 mL, 4.00 mmol, 3.0 equivalents
• the reaction vessel was placed in a heating block that had been preheated to 60 °C.
• the reaction mixture was stirred for 1.5 hours at 60 °C.
• the product mixture was then cooled to 23 °C.
• the cooled product mixture was concentrated.
• the residue obtained was partitioned between aqueous hydrochloric acid solution (1 M, 35 mL) and ethyl acetate (250 mL).
• the aqueous layer was extracted with ethyl acetate (50 mL).
• the organic layers were combined and washed with saturated aqueous sodium chloride solution (20 mL).
• the washed organic layer was dried over sodium sulfate.
• the dried solution was fdtered. Diatomaceous earth ( ⁇ 20 g) was added to the solution and the mixture was concentrated.
• Example 3N methyl [ ⁇ (3S)-3-[(tert-butoxycarbonyl)amino]-5-fluoro-7-[(2- methoxyethoxy)methoxy]-3, 4-dihydro-2H-l -benzothiopyran-6-yl ⁇ ( ⁇ [ (prop-2-en-l - yl)oxy]carbonyl ⁇ sulfamoyl)amino]acetate
• the product mixture was partially concentrated.
• the residue obtained was partitioned between ethyl acetate (75 mL) and water (10 mL).
• the organic layer was washed with saturated aqueous sodium chloride solution (10 mL).
• the washed organic layer was dried over sodium sulfate.
• the dried solution was fdtered.
• Diatomaceous earth (-15 g) was added to the solution and the mixture was concentrated.
• the residue obtained was purified by flash column chromatography (120 g Teledyne ISCO RediSep Rf Gold® silica column, elution with a gradient from 0—100% ethyl acetate— heptanes) to furnish the title compound (3.74 g, 84%).
• MS (APCI + ) m/z 655 [M+NH 4 ] + .
• Example 30 tert-butyl [(3S)-5-fluoro-7-[(2-methoxyethoxy)methoxy]-6-(1,1,4-trioxo-l/ 6 ,2,5- thiadiazolidin-2-yl)-3, 4-dihydro-2H-l -benzothiopyran- 3-yl ] carbamate
• the cooled mixture was filtered through a plug of diatomaceous earth (0.5 cm x 1.0 cm).
• the filter cake was rinsed with ethyl acetate (3 x 2.0 mL).
• the filtrates were combined and carefully diluted with aqueous hydrochloric acid solution (1 M, 25 mL).
• the resulting biphasic mixture was then transferred to a separatory funnel and the layers that formed were separated.
• the aqueous layer was extracted with ethyl acetate (2 x 50 mL).
• the organic layers were combined and the combined organic layers were washed with saturated aqueous sodium chloride solution (15 mL).
• the washed organic layer was dried over sodium sulfate.
• the dried solution was filtered and the filtrate was concentrated.
• Example 3P 5-[(3S)-3-amino-5-fluoro-7 -hydroxy- 3, 4-dihydro-2H-l-henzothiopyran-6-yl]- I ⁇ 6 , 2, 5-thiadiazolidine-l , 1, 3-trione hydrochloride
• the product mixture was concentrated.
• the residue obtained was dissolved in methanol (1.1 mL) and the solution was purified by high-performance liquid chromatography (Waters XB ridgeTM RP18 column, 5 pm, 30x 100 mm, flow rate 40 mL/minute, 5-100% gradient of acetonitrile in buffer 0.1% trifluoroacetic acid) to furnish the title compound (8.0 mg, 31%, 3 steps).
• the filtrate was added to saturated sodium thiosulfate aqueous solution (300 mL) and the resulting mixture was stirred at 20 °C for 1 hour. The mixture was transferred to a separatory funnel and the organic phase was separated. The organic fraction was washed with brine (500 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give the title compound (3 g, purity 70%, yield 77%) which was used for the next step without further purification.
• Example 3P 60 mg, 0.162 mmol
• triethylamine 67.8 pL, 0.487 mmol, 3 equivalents
• 3:2 v/v ethanol/dichloromethane 1.6 mL
• Example 5B 78.6 mg, 0.324 mmol, 2.0 equivalents
• Sodium borohydride (24.5 mg, 0.649 mmol, 4.0 equivalents) was added in one portion, and the resultant mixture was stirred for 30 minutes at ambient temperature.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.6 mL, 3.24 mmol, 20 equivalents) was slowly added, and the reaction mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8. 1 minutes 60-100% A, 8.1-9.0 minutes 100% A, 9.0-9. 1 minutes linear gradient 100-5% A, 9.1- 10.0 minutes 5% A) to afford the title compound (27.2 mg, 37.7 % yield).
• Example 6A methyl 1 -(prop-2-en- 1-yl) cyclopentane- 1 -carboxylate
• Example 6C tert-hutyl(dimethyl) ⁇ [l-(prop-2-en-l-yl)cyclopentyl]methoxy ⁇ silane
• Example 6E 5-[(3S)-5-fluoro-7-hydroxy-3-( ⁇ 2-[l-(hydroxymethyl)cyclopentyl]ethyl ⁇ amino)- 3, 4-dihydro-2H-l-benzothiopyran-6-yl ]-126, 2, 5-thiadiazolidine-l , 1, 3-trione
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.6 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.
• Example 7A methyl 2,2-dimethylpent-4-enoate [0090] The title compound was synthesized from methyl isobutyrate using the methodology described for Example 6A in 71.8 % yield.
• 1 H NMR 400 MHz CDCl 3 ) ⁇ ppm 5.57-5.89 (m, 1H), 4.91-5.16 (m, 2H), 3.56 (s, 3H), 2.27 (m, 2H), 1.17 (s, 6H).
• Example 7C tert-butyl [(2, 2-dimethylpent-4-en-l-yl)oxy]dimethylsilane
• Example 7E 5- ⁇ (3S)-5-fluoro-7-hydroxy-3-[(4-hydroxy-3,3-dimethylbutyl)amino]-3,4-dihydro- 2H-l-benzothiopyran-6-yl ⁇ -12 6 ,2,5-thiadiazolidine-l , 1,3-trione
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.1 minutes 60-100% A, 8.1-9.0 minutes 100% A, 9.0-9. 1 minutes linear gradient 100-5% A, 9. 1-10.0 minutes 5% A) to afford the title compound (10.3 mg, 14.4% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the reaction mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8. 1 minutes 60-100% A, 8.1-9.0 minutes 100% A, 9.0-9. 1 minutes linear gradient 100-5% A, 9.1- 10.0 minutes 5% A) to afford the title compound (3.3 mg, 6.5% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.1 minutes 80-100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (5.5 mg, 9.7% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.1 minutes 60-100% A, 8. 1-9.0 minutes 100% A, 9.0-9. 1 minutes linear gradient 100-5% A, 9. 1-10.0 minutes 5% A) to afford the title compound (6.5 mg, 10.8% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.
• Example 13 5-[(3S)-3-(butylamino)-5-fluoro-7-hydroxy-3,4-dihydro-2H-l- benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 112) [00100] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• Butyraldehyde (29.3 mg, 0.41 mmol, 3.0 equivalents) was added, and the reaction mixture was stirred at room temperature for 2 hours.
• Sodium borohydride (20.5 mg, 0.54 mmol, 4.0 equivalents) was added in one portion, and the resultant mixture was stirred for 30 minutes at ambient temperature.
• the reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.1 minutes 60-100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (14.1 mg, 26.8% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.1 minutes 60-100% A, 8. 1-9.0 minutes 100% A, 9.0-9. 1 minutes linear gradient 100-5% A, 9. 1-10.0 minutes 5% A) to afford the title compound (16. 1 mg, 27.6% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.1 minutes 60-100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (3.2 mg, 6.3% yield).
• Example 18 5-[(3S)-3- ⁇ [2-(3,3-difluorocyclobutyl)ethyl]amino ⁇ -5-fluoro-7-hydroxy-3,4- dihydro-2H-l-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 117) [00105] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-100% A, 8.0-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9. 1-10.0 minutes 5% A) to afford the title compound (11.7 mg, 20. 1% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.1 minutes 80-100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (21.2 mg, 37.1% yield).
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.
• reaction mixture was cooled to 0 °C in an ice bath, aqueous hydrochloric acid (2.0 M, 1.4 mL, 3.24 mmol, 20 equivalents) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.
• reaction mixture was cooled to 0 °C in an ice bath, and saturated ammonium chloride (1.0 mL) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.1 minutes 60-100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (21.2 mg, 36.4% yield).
• Example 26 5-[(3S)-5-fluoro-3- ⁇ [(l-fluorocyclopropyl)methyl]amino ⁇ -7-hydroxy-3,4- dihydro-2H-l-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 125) [00113] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• Example 27 5- [(3S)-3- ⁇ [(2,2-difluorocyclopropyl)methyl] amino ⁇ -5-fluoro-7-hydroxy-3,4- dihydro-2H-l-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 126) [00114] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• 2,2-Difluorocyclopropane-l-carbaldehyde (43.0 mg, 0.41 mmol, 3.0 equivalents) was added, and the reaction mixture was stirred at room temperature for 2 hours.
• Sodium borohydride (20.5 mg, 0.54 mmol, 4.0 equivalents) was added in one portion, and the resultant mixture was stirred for 30 minutes at ambient temperature.
• the reaction mixture was cooled to 0 °C in an ice bath, and saturated ammonium chloride (1.0 mL) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Example 28 5-[(3S)-5-fluoro-7-hydroxy-3- ⁇ [(3-methyloxetan-3-yl)methyl]amino ⁇ -3,4- dihydro-2H-l-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 127) [00115] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• reaction mixture was cooled to 0 °C in an ice bath and saturated ammonium chloride (1.0 mL) was slowly added, and the mixture was partially concentrated under a stream of nitrogen.
• Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100A AXIATM column (50 mm x 30 mm).
• the solution was diluted with aqueous ammonium bicarbonate (0.025 M in water, acidified to pH 7 by addition of dry ice) and loaded onto a 30 g Biotage® Sfar C18 column, where it was purified by a 10-100% gradient of methanol in 0.025 M ammonium bicarbonate in water (acidified to pH 7 by addition of dry ice) to yield the title compound (17.8 mg, 0.041 mmol, 45.4 % yield).
• the solution was diluted with aqueous ammonium bicarbonate (0.025 M in water, acidified to pH 7 by addition of dry ice) and loaded onto a 30 g Biotage® Sfar C18 column, where it was purified by a 10-100% gradient of methanol in 0.025 ammonium bicarbonate in water (acidified to pH 7 by addition of dry ice) to yield the title compound (10.2 mg, 0.025 mmol, 28.2 % yield).
• Example 32 5-[(3S)-5-fluoro-7-hydroxy-3- ⁇ [3-(1H-pyrazol-l-yl)propyl]amino ⁇ -3,4- dihydro-2H-1-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 131) [00119] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 ⁇ L, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• Example 33 5-[(3S)-5-fluoro-7-hydroxy-3- ⁇ [2-(l-methylcyclopropyl)ethyl]amino ⁇ -3,4- dihydro-2H-1-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 132) [00120] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• reaction mixture was cooled to 0 °C in an ice bath, and saturated ammonium chloride (1.0 mL) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-60% A, 8.0-8.1 minutes 60-100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (12.0 mg, 21.4% yield).
• reaction mixture was cooled to 0 °C in an ice bath, and saturated ammonium chloride (1.0 mL) was slowly added. Then the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100A AXIATM column (50 mm * 30 mm). A gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-100% A, 8.0-9.0 minutes 100% A, 9.0-9.
• Example 36 5-[(3S)-5-fluoro-7-hydroxy-3- ⁇ [(3-phenylcyclobutyl)methyl]amino ⁇ -3,4- dihydro-2H-l-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 135) [00123] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• Example 37 5- ⁇ (3S)-5-fluoro-7-hydroxy-3-[(3-phenylpropyl)amino]-3,4-dihydro-2H-l- benzothiopyran-6-yl ⁇ -l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 136)
• reaction mixture was cooled to 0 °C in an ice bath, and saturated ammonium chloride (1.0 mL) was slowly added. The mixture was then partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.1 minutes 80-100% A, 8.1-9.0 minutes 100% A, 9.0-9. 1 minutes linear gradient 100-5% A, 9. 1-10.0 minutes 5% A) to afford the title compound (13.4 mg, 22% yield).
• Example 38 5-[(3S)-3- ⁇ [3-(2,2-difluoroethoxy)propyl]amino ⁇ -5-fluoro-7-hydroxy-3,4- dihydro-2H-l-benzothiopyran-6-yl]-l ⁇ 6 , 2, 5-thiadiazolidine-l, 1,3-trione (Compound 137) [00125] In a 4 mL vial were combined the product of Example 3P (50 mg, 0.14 mmol) and triethylamine (57 pL, 0.41 mmol, 3 equivalents) in 3:2 v/v ethanol/dichloromethane (1.4 mL) to give a suspension.
• reaction mixture was cooled to 0 °C in an ice bath, and saturated ammonium chloride (1.0 mL) was slowly added, and the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0- 0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.1 minutes 80-100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (16.5 mg, 28.5% yield).
• reaction mixture was cooled to 0 °C in an ice bath, and saturated ammonium chloride (1.0 mL) was slowly added. Then the mixture was partially concentrated under a stream of nitrogen. Methanol (1 mL) was added, and the mixture was purified via reverse-phase preparative HPLC on a Phenomenex® Luna® C8(2) 5 pm 100 ⁇ AXIATM column (50 mm x 30 mm).
• a gradient of methanol (A) and 25 mM ammonium bicarbonate buffer (pH 7) in water (B) was used, at a flow rate of 40 mL/minute (0-0.5 minutes 5% A, 0.5-8.0 minutes linear gradient 5-80% A, 8.0-8.1 minutes 80- 100% A, 8.1-9.0 minutes 100% A, 9.0-9.1 minutes linear gradient 100-5% A, 9.1-10.0 minutes 5% A) to afford the title compound (23.5 mg, 32.8% yield).
• DMEM Dulbecco's Modified Eagle Medium
• DMSO dimethyl sulfoxide
• DTT dithiothreitol
• EDTA ethylenediaminetetraacetic acid
• EGTA ethylene glycol- bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid
• HEPES 4-(2-hydroxyethyl)piperazine-l- ethane sulfonic acid
• IFN ⁇ for interferon gamma
• Tween® 20 polyethylene glycol sorbitan monolaurate.
• Example 43 Mobility Shift Assay (MSA) used to determine potency of PTPN2 inhibitors
• Compound activity was determined using in house His tagged PTPN2 (TC45) protein (SEQ ID NO: 1) in an in vitro enzymatic reaction.
• the enzymatic assay used to determine activity was a mobility shift assay using a LabChip EZ Reader by Caliper Life Sciences.
• the enzymatic reaction was carried out in assay buffer (50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM EDTA, 0.01% Tween® 20, and 2 mM DTT).
• the compounds were dispensed on a white 384 well ProxiPlateTM (PerkinElmer Catalog# 6008289) plate using the Labcyte Echo at varying concentrations (12 point, 1:3 dilution).
• the enzyme (at 0.5 nM) was incubated with compound for 10 minutes at room temperature. Thereafter, the substrate (phosphorylated insulin receptor probe sequence: ((OG488)-(NH-CH 2 -CH 2 -O-CH 2 -CH 2 -O-CH 2 -CO)-T-R-D-I-(PY)-E-T- D-Y-Y-R-K-K-NH 2 ) (SEQ ID NO: 2) was added at 2 pM to the plates and incubated for another 10 minutes at room temperature.
• substrate phosphorylated insulin receptor probe sequence: ((OG488)-(NH-CH 2 -CH 2 -O-CH 2 -CH 2 -O-CH 2 -CO)-T-R-D-I-(PY)-E-T- D-Y-Y-R-K-K-NH 2 ) (SEQ ID NO: 2) was added at 2 pM to the plates and incubated for another 10 minutes at room temperature.
• Each plate had a 100% control (inhibitor: 4-bromo-3-(2- oxo-2 -propoxyethoxy)-5 -(3 - ⁇ [ 1 -(phenylmethanesulfonyl)piperidin-4- yl]amino ⁇ phenyl)thiophene-2 -carboxylic acid) and 0% control (DMSO), which were used to calculate % inhibition. The % inhibition was then used to calculate the IC 5 0 values.
• Example 44 Mobility Shift Assay (MSA) used to determine potency of PTPN1 inhibitors
• Compound activity was determined using in house His tagged full-length PTPN 1 protein (SEQ ID NO: 3) in an in vitro enzymatic reaction.
• the enzymatic assay used to determine activity is a mobility shift assay using a LabChip EZ Reader by Caliper Life Sciences.
• the enzymatic reaction was carried out in assay buffer (50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM EDTA, 0.01% Tween® 20, and 2 mM DTT).
• the compounds were dispensed on a white 384 well ProxiPlateTM (PerkinElmer Cat # 6008289) plate using a Labcyte Echo® liquid handler at varying concentrations (12 point, 1:3 dilution).
• the enzyme (at 0.5 nM) was incubated with compound for 10 minutes at room temperature.
• the substrate phosphorylated insulin receptor probe sequence: ((OG488)-(NH-CH 2 -CH 2 -O-CH 2 -CH 2 -O-CH 2 -CO)-T-R-D-I- (PY)-E-T-D-Y-Y-R-K-K-NH2) (SEQ ID NO: 2) was added at 2 pM to the plates and incubated for another 10 minutes at room temperature.
• Each plate had a 100% control (inhibitor: 4-bromo-3-(2-oxo-2-propoxyethoxy)-5-(3- ⁇ [l- (phenylmethanesulfonyl)piperidin-4-yl]amino ⁇ phenyl)thiophene-2-carboxylic acid) and 0% control (DMSO), which were used to calculate % inhibition. The % inhibition was then used to calculate the IC 5 0 values.
• Table 1 summarizes the IC 5 0 data obtained using the PTPN2 MSA assay and the PTPN1 MSA assay for exemplary compounds of the disclosure.
• “A” represents an IC 5 0 of less than 10 nM
• “B” an IC 5 0 of between 10 nM and 100 nM
• “C” an IC 5 0 of greater than 100 nM to 100 nM.
• Table 1 IC 5 0 values of exemplary compounds of the disclosure in the PTPN2 and PTPN1 Mobility Shift Assays (MSA).
• MSA Mobility Shift Assays
• Example 45 B16F10 (Murine Melanoma Cells) Phospho-STATl HTRF Proximal Pharmacodynamic (PD) Assay
• B16F10 cells were grown and maintained in high glucose DMEM (Gibco,
• the cells were dosed with the compounds of interest using an Echo Liquid Handler (Beckman Coulter, Brea, CA) at 50 pM top dose with 3 -fold dilutions down to 0.002679 pM for a 10-point dose response.
• the plate was incubated for 3 hours at 37 °C and subsequently treated with recombinant mouse IFNy (R&D Systems, Catalog* 485-MI, Minneapolis, MN; 100 nM final concentration) for 10 minutes at 37 °C to induce STAT1 phosphorylation followed by 3.3 pM staurosporine treatment for 1 hour at 37 °C to terminate phosphorylation.
• the antibody master mix was then dispensed at 4 pL per well into a 384 ProxiPlate Plus (PerkinElmer, part* 6008289, Waltham, MA) and 16 pL of lysate was added from the Coming plate to the Proxiplate using a VIAFLO 384 (INTEGRA).
• the plate was incubated for 3 hours at room temperature and read on an EnVision® (Perkin Elmer) plate reader with laser excitation at 335 nm and emission at 665 nm.
• Dotmatics Studies (Bishop’s Stortford, UK) was utilized to generate all dose-response curves and calculate EC50s and are shown in Table 2.
• Table 2 EC 50 values in B16F10 IFNy-induced STAT1 phosphorylation (pSTATl) cell assay.
• Example 46 Comparative Mobility Shift Assay (MSA) and B16F10 pSTATl HTRF Proximal Pharmacodynamic (PD) Assay for Thiochromane Compounds of the Disclosure and Corresponding Chromane Analogs.
• MSA PTPN2 Mobility Shift Assays
• pSTATl IFN ⁇ -induced STAT1 phosphorylation

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=84887566

Family Applications (1)

Country Status (8)

Cited By (1)

Citations (4)

• 2022
  • 2022-11-10 MX MX2024005656A patent/MX2024005656A/es unknown
  • 2022-11-10 WO PCT/US2022/049581 patent/WO2023086495A1/en not_active Ceased
  • 2022-11-10 JP JP2024527749A patent/JP2024543451A/ja active Pending
  • 2022-11-10 US US18/709,204 patent/US20250042894A1/en active Pending
  • 2022-11-10 AU AU2022386164A patent/AU2022386164A1/en active Pending
  • 2022-11-10 EP EP22839527.3A patent/EP4430039A1/en active Pending
  • 2022-11-10 CA CA3236853A patent/CA3236853A1/en active Pending
  • 2022-11-10 CN CN202280088452.2A patent/CN118556055A/zh active Pending

Patent Citations (4)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events